College Station is suddenly at the center of a sci-fi sounding experiment brought into real life. Texas A&M researchers say a two-dose nasal spray made from microscopic parcels taken from human neural stem cells reversed hallmarks of brain aging in older mice. Treated animals had lower inflammation, better mitochondrial function in neurons and measurable gains on memory and recognition tests within weeks. The team reports that the benefits lasted for months after dosing and showed up in both male and female animals.
How the spray works
The experimental treatment loads extracellular vesicles, tiny membrane-bound packages that carry microRNAs, into a nasal formulation that reaches the hippocampus and delivers regulatory RNA to immune and neuronal cells. The study, published in the Journal of Extracellular Vesicles, reports that specific microRNAs in the vesicles tamp down inflammasome and interferon signaling while boosting genes tied to mitochondrial respiratory chains. Those mechanistic results were also highlighted in a university news release from Texas A&M.
Results in mice
In the paper's experiments, late-middle-aged 18-month-old mice, a common stand-in for roughly 60-year-old humans, received two intranasal doses and later outperformed untreated peers in object-recognition and change-detection tasks. Brain tissue showed reduced astrocyte hypertrophy, fewer microglial clusters and lower oxidative stress after treatment, and the team reported that both behavioral and cellular benefits persisted for months. These findings were summarized by The Detroit News.
Patent, human testing and hurdles
Lead author Ashok Shetty said, "We are seeing the brain's own repair systems switch on, healing inflammation and restoring itself," according to Texas A&M. The researchers have filed a U.S. patent and say the work was supported by the National Institute on Aging as they plan to develop a version that could be tested in people. At the same time, experts warn that extracellular vesicle therapies face manufacturing, potency and regulatory challenges that must be addressed before safe, large-scale human trials can begin, according to a review in Stem Cells and Development.
Why it matters
The work is still firmly in the preclinical stage, but it lands at a moment when dementia risk is climbing. A 2025 analysis in Nature Medicine estimated that annual new dementia cases in the U.S. could rise from about 514,000 in 2020 to roughly 1 million by 2060. The Texas A&M team frames neuroinflammaging, chronic low-grade inflammation in memory circuits, as a targetable mechanism for age-related cognitive decline. If the nasal-spray approach ever proves safe and effective in people, researchers say it might offer a less invasive way to blunt that process.
Bottom line, the paper offers an encouraging mechanistic proof of concept and fast, durable effects in mice, but human testing and manufacturing work remain significant hurdles. For now, the finding is a promising step that will need careful, tightly regulated follow-through before it comes anywhere near a clinic.
